接受抗逆转录病毒治疗的患者中Cobas 6800系统检测并定量到更多HIV-1 RNA
该研究回顾性比较了CAP/CTM与Cobas 6800系统在HIV-1病毒载量检测中的差异。在长期病毒载量低于50拷贝/mL的患者中,换用Cobas 6800后靶标检出结果和低水平病毒血症显著增加,病毒载量≥20拷贝/mL的患者比例约为原来的两倍。作者提示医生和患者应知晓不同检测方法间的差异,研究需注明所用定量方法。
要点
- 换用Cobas 6800后,病毒载量≥20拷贝/mL的患者比例约为CAP/CTM时的两倍。
- 在病毒载量持续低于50拷贝/mL的患者中,换用Cobas 6800后靶标检出结果频率显著增加。
- 不同HIV-1 RNA定量方法的结果存在差异,研究应注明所用检测方法。
核心结论
- Cobas 6800揭示了CAP/CTM未检测到的残余或低水平HIV-1 RNA,导致病毒载量≥20拷贝/mL的患者数量约为原来的两倍。
- 医生和患者应知晓不同检测方法间可能存在结果差异,研究注明所用定量方法至关重要。
研究设计与样本
- 回顾性研究,比较换用Cobas 6800前后连续病毒载量结果。
- 第1组:200例患者,换用Cobas 6800前用CAP/CTM检测病毒载量持续<50拷贝/mL至少3年。
- 第2组:35例患者,使用Cobas 6800时确认存在低水平病毒血症。
- 统计分析采用McNemar配对检验或Fisher精确检验。
主要发现
- 第1组中,CAP/CTM检测结果中靶标检出结果<25%的患者,换用Cobas 6800后靶标检出结果(低于或高于定量下限)频率显著增加(P<0.0001)。
- 第1组中,Cobas 6800检测至少有1次病毒载量≥20拷贝/mL的患者比例显著高于CAP/CTM(37.0% vs 18.5%;P<0.0001)。
- 第1组中,Cobas 6800检测至少有1次病毒载量≥50拷贝/mL的患者比例显著高于CAP/CTM(6.5% vs 0%;P=0.0009)。
- 第2组中,Cobas 6800检测至少有1次病毒载量≥20拷贝/mL的患者比例显著高于CAP/CTM(100% vs 66%;P=0.0015)。
- 第2组中,Cobas 6800检测至少有1次病毒载量≥50拷贝/mL的患者比例显著高于CAP/CTM(97% vs 40%;P<0.0001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Target-detected (TD) results or low-level viraemia (LLV) can be observed in HIV-1 patients on ART, which regularly raises questions. OBJECTIVES: We describe here the impact on HIV-1 RNA quantification of switching from the COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) to the Cobas 6800 system (C6800), based on analyses of viraemia close to the lower limit of quantification (LLoQ). PATIENTS AND METHODS: We retrospectively selected two groups of patients: 200 individuals whose viral loads (VLs) were consistently <50 copies/mL with CAP/CTM for at least 3 years before switching to C6800 (group 1), and 35 other patients with confirmed LLV when C6800 was in use (group 2). In both groups, we compared several consecutive VL results performed before and after the change of quantification assay. Analyses were performed with McNemar's paired tests or Fisher's exact tests. RESULTS: In group 1, the frequency of TD results (below or above the LLoQ) increased significantly after the switch to C6800 for patients with <25% of results being TD for VLs performed with CAP/CTM (P < 0.0001). Significantly more patients had at least one VL ≥20 or ≥50 copies/mL with C6800, in both group 1 (37.0% versus 18.5%; P < 0.0001 and 6.5% versus 0%; P = 0.0009, respectively) and group 2 (100% versus 66%; P = 0.0015 and 97% versus 40%; P < 0.0001, respectively). CONCLUSIONS: C6800 revealed residual or low-level HIV-1 RNA that was not detected with CAP/CTM, resulting in twice as many patients being found to have a VL ≥20 copies/mL. Physicians and patients should be aware of possible differences in results between assays, and it is crucial to specify the quantitative assay used in studies.
引用
- Wirden M, Palich R, Abdi B, et al. More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy. J Antimicrob Chemother. 2022. PMID: 35640662. doi:10.1093/jac/dkac174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。